Pyrazine based inhibitors of glycogen synthase kinase 3

Details Pyrazine based inhibitors of glycogen synthase kinase 3 Pyrazine based inhibitors of glycogen synthase kinase 3

2005-09-27

2005-09-27

Lukton, David (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S248000, C514S183000, C514S279000, C514S290000, C546S193000

Reexamination Certificate

active

06949547

ABSTRACT:
New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

REFERENCES:
patent: 07 033752 (1995-02-01), None
patent: WO 98/16528 (1998-04-01), None
patent: WO 98/43641 (1998-10-01), None
patent: WO 99/03838 (1999-01-01), None
Benincori et al., “Studies of the Fischer Indole Synthesis: Rearrangements of Five-, Six-, and Seven-Membered Cyclic Hydrazones of Pyrazoline, Tetrahydropyridazine and Tetrahydro-1, 2-diazepine Series in Polyphosphoric Acid,”J. Chem. Soc., Perkin Trans.,pp. 2139-2145, 1991.

Affiliated with

Also associated with

Rating

Pyrazine based inhibitors of glycogen synthase kinase 3 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrazine based inhibitors of glycogen synthase kinase 3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazine based inhibitors of glycogen synthase kinase 3 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3385819